- Home
- HRTX
as 09-05-2025 4:00pm EST
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 206.9M | IPO Year: | 1987 |
| Target Price: | $4.50 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $2.68 | Next Earning Date: | 08-08-2025 |
| Revenue: | $149,694,000 | Revenue Growth: | 9.78% |
| Revenue Growth (this year): | 10.62% | Revenue Growth (next year): | 12.99% |
Stock Insider Trading Activity of Heron Therapeutics Inc. (HRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Adam | HRTX | N/A | Aug 8 '25 | Buy | $1.50 | 1,766,546 | $2,649,819.00 | 8,753,290 | |
| Rubric Capital Management LP | HRTX | N/A | Aug 8 '25 | Buy | $1.50 | 2,387,225 | $3,580,837.50 | 29,100,728 |
Latest Heron Therapeutics Inc. News
HRTX Breaking Stock News: Dive into HRTX Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
HC Wainwright Initiates Coverage on Heron Therapeutics With Buy Rating, $6 Price Target
Investopedia
3 months ago
Ulta Stock Jumps as Beauty Product Spending Continues
GlobeNewswire
3 months ago
Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
GlobeNewswire
3 months ago
Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
Benzinga
3 months ago
Northrop Grumman Raises $1 Billion Via Debt
GlobeNewswire
3 months ago
Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
Newsfile
3 months ago
Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025
GlobeNewswire
3 months ago
TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast
Compare HRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRTX Heron Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.